A 28-year-old man with diabetes mellitus (HbA1c 9.2%) presents with a 4-week history of scaly, erythematous patches on both feet with central clearing and a raised border. Microscopy shows septate hyphae. He has been using over-the-counter antifungal powder daily for 2 weeks without relief. What is the most appropriate next step in management?

Explanation

## Clinical Presentation and Diagnosis This patient has **tinea pedis** (athlete's foot) with: - Classic presentation: scaly patches with central clearing and raised border - Confirmed dermatophyte infection (septate hyphae on microscopy) - Risk factor: uncontrolled diabetes (HbA1c 9.2%) - Failed topical therapy after 2 weeks ## Why Systemic Therapy Is Indicated **Key Point:** Topical antifungals fail in tinea pedis when: 1. Poor adherence or inadequate application 2. Thick hyperkeratotic lesions with poor drug penetration 3. Immunocompromised state (diabetes with poor glycemic control) 4. Extensive involvement (both feet) This patient meets multiple criteria for systemic therapy escalation. ## Terbinafine vs. Fluconazole for Tinea Pedis | Feature | Terbinafine | Fluconazole | |---------|-------------|-------------| | **Mechanism** | Squalene epoxidase inhibitor (fungicidal) | Lanosterol demethylase inhibitor (fungistatic) | | **Efficacy vs. dermatophytes** | Superior (>90% cure) | Moderate (70–80% cure) | | **Duration for tinea pedis** | 2–4 weeks | 4–6 weeks | | **Dosing** | 250 mg daily | 150 mg weekly or 200 mg daily | | **First-line status** | Yes, for dermatophytes | No; reserved for candidiasis or azole-resistant cases | | **Hepatotoxicity** | Rare (<1%) | Rare but more common than terbinafine | **High-Yield:** Terbinafine is the **preferred systemic agent** for tinea pedis caused by *Trichophyton* species (most common) because it achieves higher skin concentrations and requires shorter treatment duration. ## Critical Role of Glycemic Control **Clinical Pearl:** Uncontrolled diabetes impairs neutrophil function and cell-mediated immunity, increasing susceptibility to fungal infections and delaying healing. Optimizing glycemic control (target HbA1c <7%) is **essential** for: - Reducing infection recurrence - Accelerating response to antifungal therapy - Preventing complications (secondary bacterial infection, cellulitis) **Mnemonic for diabetes complications in tinea:** **FUNGI** = **F**ungal infections, **U**lceration risk, **N**europathy, **G**lycemic control needed, **I**mmunity impaired. ## Management Algorithm ```mermaid flowchart TD A[Tinea pedis confirmed by KOH]:::outcome --> B{Topical therapy response?}:::decision B -->|Good response| C[Continue topical 2-4 weeks]:::action B -->|Failed after 2 weeks| D[Assess glycemic control & extent]:::decision D --> E[Uncontrolled DM or extensive disease]:::outcome E --> F[Start oral terbinafine 250 mg daily]:::action F --> G[Optimize HbA1c target <7%]:::action G --> H[Review at 2-4 weeks]:::decision H -->|Cured| I[Counseling: foot hygiene, moisture control]:::action H -->|Persistent| J[Repeat KOH or culture]:::action ``` ## Counseling and Prevention After systemic therapy: - Keep feet dry (especially between toes) - Use antifungal powder in high-moisture areas - Avoid walking barefoot in communal areas - Change socks if feet become damp - Monitor for recurrence (common in diabetics)